Genenta Science S.p.A. American Depositary Shares (GNTA)

FairStock Score: 44/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham-style investor, I start with business quality and a margin of safety. Genenta Science is described as a strategic consolidator in Italian national-security-regulated sectors, but it has just 9 employees and a $16.7 million market cap at the close on 2026-10-13. That is a shell-like profile, and the supplied data show no revenue or profit growth figures at all. The Lynch category is none because there are only 0 years of filed annual results, needing 3, so there is no durable operating record to judge. Financial health is poor: FairStock calculates P/E at -1.90, ROE at -38.03%, ROCE at -17.67%, Piotroski F-Score 1/9, and Altman Z-Score -0.70. The D/E of 0.35 is not alarming by itself, but it does not offset persistent losses. The one apparent valuation attraction is P/B of 0.67: the stock trades below accounting book value. Graham might ask whether those assets are real and earning power exists; without profits, a discount to book can be a value trap. The 52-week range of $0.55 to $10.00 shows extreme volatility and a collapsed price. Beta of 0.72 suggests lower historical market sensitivity, but that does not reduce business risk. A moat is not evident from the data: the strategy may target regulated sectors, but there is no evidence of pricing power, recurring revenue, or successful acquisitions. Growth trajectory is unmeasurable because revenue and profit growth are listed as N/A. I would need filed results and a proven acquisition record before treating this as an investment rather than a speculation.

In plain English: Genenta Science is a tiny Italian company that aims to buy private businesses in security-related fields such as aerospace, defense, and biosecurity. The business looks weak today: it is losing money, has almost no reported track record, and one financial-health measure points to distress. The share price is low compared with its accounting value, but that discount may reflect real problems rather than a simple bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer